Published in Women's Health Weekly, June 10th, 2004
This compares to revenues of $0.7 million and a net loss of $4.2 million, or $0.08 per share for the first quarter 2003.
At March 31, 2004, Genelabs had $25.8 million in cash and short-term investments.
"During the first quarter of 2004 Genelabs made important progress in all facets of our business," stated James A.D. Smith, president and chief executive officer. "We completed enrollment into our confirmatory clinical trial of Prestara for lupus [systemic lupus erythematosus], entered...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly